This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.
In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.
In your application messsage, please share your background and what you can contribute to the group.
Company Overview and News
VANCOUVER, British Columbia, July 03, 2018 (GLOBE NEWSWIRE) -- K92 Mining Inc. (TSXV:KNT) (OTCQX:KNTNF) (“K92” or the “Company”) reports that it has received CAN $2.73 million through an exercise of 2.6 million common share purchase warrants, which were exercisable at $1.05 per share.
VANCOUVER, BC / ACCESSWIRE / June 26, 2018 / Doubleview Capital Corp. ("Doubleview") (TSX-V: DBV, OTC PINK: DBLVF) is pleased to announce that Mr. Stuart (Tookie) Angus has been appointed as Mergers and Acquisitions ("M&A") Advisor to the Company's Board of Directors, effective June 26, 2018. Mr. Angus brings over 40 years experience in M & A, structuring and financing significant international exploration, development and mining ventures.
NSU KGC RVRLF KNTNF K FQVLF RMC DBV FQM SMN
VANCOUVER, British Columbia, June 04, 2018 (GLOBE NEWSWIRE) -- K92 Mining Inc. (TSX-V:KNT) (OTCQX:KNTNF) (“K92” or the “Company”) is pleased to announce results from the continuing grade control drilling of the Kora North Extension.
Note1 - a non-IFRS measure computed in the Company’s MD&A in the non-IFRS performance measures section.
VANCOUVER, British Columbia, May 17, 2018 (GLOBE NEWSWIRE) -- K92 Mining Inc. – (TSX-V:KNT) (OTCQX:KNTNF) (“K92”) is pleased to announce results from the continuing grade control drilling of the Kora North Extension.
VANCOUVER, BC / ACCESSWIRE / May 1, 2018 / Nexus Gold Corp. (''Nexus'' or the ''Company'') (TSX-V: NXS; OTC PINK: NXXGD; FSE: N6E) reports the following management and board changes:
AULGF GFI.WI NXXGF NXS KNTNF AU GFI AGG NXXGD GFIOF
VANCOUVER, British Columbia, May 01, 2018 (GLOBE NEWSWIRE) -- K92 Mining Inc. (“K92” or “the Company”) (TSXV: KNT) (OTCQX:KNTNF) is pleased to announce that, at the opening of trading on May 1, 2018, it will begins trading on OTCQX under the symbol “KNTNF.” K92 has qualified to trade on the OTCQX® Best Market in the United States. OTCQX is reserved for companies that meet high financial standards, follow best practice corporate governance, demonstrate compliance with U.
VANCOUVER, British Columbia, April 30, 2018 (GLOBE NEWSWIRE) -- K92 Mining Inc. (“K92” or “the Company”) (TSXV:KNT) (OTCQB:KNTNF) announces the grant of 2,230,000 stock options to directors, officers, employees and consultants of the Company, pursuant to the terms of the Company’s Stock Option Plan. The options are exercisable at $0.85 per share, expire on April 30, 2023, and vest in quarterly increments over 12 months from the date of grant.
VANCOUVER, British Columbia, April 25, 2018 (GLOBE NEWSWIRE) -- K92 Mining Inc. (“K92”) (TSXV:KNT) (OTCQB:KNTNF) is pleased to announce results from the continuing grade control drilling of the Kora North Extension.
2018-07-13 - Asif
Overview Catabasis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics based on its proprietary Safely Metabolized And Rationally Targeted linker, or SMART LinkerSM, drug discovery platform. The company's SMART Linker drug discovery platform enables it to engineer product candidates that can simultaneously modulate multiple targets in a disease. The company's proprietary product candidates impact pathways that are central to diseases where efficacy may be optimized by a multiple target approach. Catabasis Pharmaceuticals has applied its SMART Linker drug discovery platform to build an internal pipeline of product candidates for rare diseases, its primary focus, and plan to pursue partnerships to develop additional product candidates. The company's lead product candidate is edasalonexent, formerly known as CAT-1004, which the company believe has the potential to be a disease-modifying...
2018-07-09 - Asif
Overview Walmart Inc. helps people around the world save money and live better – anytime and anywhere – in retail stores and through eCommerce. Through innovation, Walmart is striving to create a customer-centric experience that seamlessly integrates its eCommerce and retail stores in an omni-channel offering that saves time for its customers. Each week, the company serve nearly 270 million customers who visit its more than 11,700 stores and numerous eCommerce websites under 65 banners in 28 countries. The company's strategy is to lead on price, invest to differentiate on access, be competitive on assortment and deliver a great experience. Leading on price is designed to earn the trust of its customers every day by providing a broad assortment of quality merchandise and services at everyday low prices ("EDLP"). EDLP is its pricing philosophy under which the company price items at a low price every day so its customers trust that its prices will not change under frequent prom...
2018-07-06 - Asif
Overview Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from chronic pain. Nevro has developed and commercialized the Senza® spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain. The company's proprietary paresthesia-free HF10TM therapy, delivered by its Senza system, was demonstrated in its SENZA-RCT study to be superior to traditional SCS therapy with it being nearly twice as successful in treating back pain and 1.5 times as successful in treating leg pain when compared to traditional SCS therapy. Comparatively, traditional SCS therapy has limited efficacy in treating back pain and is used primarily for treating leg pain, limiting its market adoption. The company's SENZA-RCT study, along with its European studies, represents what the company believe is the most robust body of clinical evidence for any SCS therapy. The compa...
as of ET